Anti-PCSK9 antibodies and use thereof
First Claim
1. An isolated antibody or antigen-binding fragment thereof that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), that contains a variable heavy chain which comprises the CDR1 sequence of SEQ ID NO:
- 84, the CDR2 sequence of SEQ ID NO;
86, and the CDR3sequence of SEQ ID NO;
88 and contains a variable light chain which comprises the CDR1sequence of SEQ ID NO;
104, the CDR2 sequence of SEQ ID NO;
106, and the CDR3sequence of SEQ ID NO;
108.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.
329 Citations
21 Claims
-
1. An isolated antibody or antigen-binding fragment thereof that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), that contains a variable heavy chain which comprises the CDR1 sequence of SEQ ID NO:
- 84, the CDR2 sequence of SEQ ID NO;
86, and the CDR3sequence of SEQ ID NO;
88 and contains a variable light chain which comprises the CDR1sequence of SEQ ID NO;
104, the CDR2 sequence of SEQ ID NO;
106, and the CDR3sequence of SEQ ID NO;
108. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- 84, the CDR2 sequence of SEQ ID NO;
Specification